Time filter

Source Type

Shanghai, China

Han Y.,Minhang Branch | Qu X.-L.,Minhang Branch | Chai Y.-X.,Minhang Branch | Wang B.,Minhang Branch | And 2 more authors.
Tumor | Year: 2013

Objective: To evaluate the efficacy and toxicity of docetaxel in combination with S-1 as neoadjuvant chemotherapy for patients with advanced gastric cancer and observe the postoperative complications. Methods: From July 2011 to December 2012, 30 patients with advanced gastric cancer were admitted to our hospital and treated with two cycles of DS remedy (docetaxel 75 mg/m 2 on day 1 and oral S-1 60 mg/m2 per day on day 1 to 14, repeated every 3 weeks) as neoadjuvant chemotherapy. The efficacy and toxicity were evaluated after two cycles of DS remedy were completed. Results: Of 30 patients, two achieved CR (complete response), 21 achieved PR (partial response), 7 achieved SD (stable disease), 0 achieved PD (progressive disease), and the response rate (CR+PR) was 76.7% (23/30). All 30 patients received surgery after neoadjuvant chemotherapy. Twenty-six patients (86.7%) received radical surgery, and twenty-three of them (88.5%) received D2 lymph node dissection; the remaining four patients (13.3%) received exploratory celiotomy. No mortality was observed in the study. The common adverse reactions included neutropenia, nausea and vomiting. The patients with effective response to neoadjuvant chemotherapy continued to receive the original scheme. Conclusion: The DS remedy as neoadjuvant chemotherapy is highly active, safe and well tolerated in patients with advanced gastric cancer. Copyright © 2013 by TUMOR. Source

Discover hidden collaborations